Press Releases Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Delayed Nasdaq Other stock markets 13:24:52 2024-05-10 EDT			5-day change	1st Jan Change
0.4998 ^USD	+5.22%		+2.95%	-52.41%

05-09	Certain Options of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.	CI
05-09	Certain Common Stock of Evoke Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications	04-17	AQ
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer	03-21	AQ
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results	03-14	AQ
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024	03-07	AQ
Evoke Pharma Announces Closing of $7.5 Million Public Offering	02-14	AQ
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million	02-09	AQ
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray	11-30	AQ
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent	11-27	AQ
Evoke Pharma : Failure to Satisfy Listing Rule - Form 8-K	11-22	PU
Evoke Pharma - United States Patent and Trademark Office Grants another Formulation Patent Covering GIMOTI	11-15	AQ
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI	11-14	AQ
Evoke Pharma Reports Third Quarter 2023 Financial Results	11-09	AQ
Evoke Pharma and EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide	11-01	AQ
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023	23-10-31	AQ
Evoke Pharma's Abstract Entitled 'Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients' to Be Presented at The American College of Gastroenterology 2023	23-10-19	AQ
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting	23-10-18	AQ
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®	23-09-14	AQ
Evoke Pharma Reports Second Quarter 2023 Financial Results	23-08-10	AQ
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society Meeting	23-08-08	AQ
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting	23-08-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Press Releases

Filters